How can we bring high drug doses to the lung?

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 1, 2014, Pages 1-6

  Claus, Sarah ^a   Weiler, Claudius ^b   Schiewe, Joerg ^b   Friess, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Antibiotic inhalation; Dry powder inhalation; High dose delivery; Inhalation devices; Lung delivery; Particle engineering; Pulmonary drug delivery

Indexed keywords

DRUG CARRIER; LACTOSE;

AEROSOL; AIRFLOW; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRY POWDER; DRY POWDER INHALER; ERECTILE DYSFUNCTION; FLOW RATE; FREEZE DRYING; HUMAN; INHALER; LUNG; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; POWDER FLOW; REVIEW; SOFT MIST INHALER; SPRAY DRYING; SUPERCRITICAL FLUID;

ANTIBIOTIC INHALATION; DRY POWDER INHALATION; HIGH DOSE DELIVERY; INHALATION DEVICES; LUNG DELIVERY; PARTICLE ENGINEERING; PULMONARY DRUG DELIVERY;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LUNG; METERED DOSE INHALERS; PHARMACEUTICAL PREPARATIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84896713178     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.11.005     Document Type: Review

References (88)

1. D.E. Geller Aerosol antibiotics in cystic fibrosis Respir. Care 54 2009 658 670
2. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Brit. J. Clin. Pharmacol. 56 2003 588 599
3. N. Crowther-Labiris, A. Holbrook, H. Chrystyn, S. MacLeod, and M. Newhouse Dry Powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis Am. J. Respir. Crit. Care Med. 160 1999 1711 1716
4. I.J. Smith, and M. Parry-Billings The inhalers of the future? A review of dry powder devices on the market today Pulm. Pharmacol. Ther. 16 2003 79 95
5. S.P. Newman A comparison of lung deposition patterns between different asthma inhalers J. Aerosol Med. 8 1995 21 27
6. J. Weers, A. Clark, and P. Challoner High dose inhaled powder delivery: challenges and techniques R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, Respiratory Drug Delivery IX 2004 Davis Healthcare International Publishing (River Grove, IL, USA) Palm Desert, CA, USA 281 288
7. K.C. Kesser, and D.E. Geller New aerosol delivery devices for cystic fibrosis Respir. Care 54 2009 754 768
8. S.P. Newman, K.P. Steed, S.J. Reader, G. Hooper, and B. Zierenberg Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer J. Pharm. Sci. 85 1996 960 964
9. M.B. Dolovich, and R. Dhand Aerosol drug delivery: developments in device design and clinical use Lancet 377 2011 1032 1045
10. L. Krasno, M. Karp, and P.S. Rhoads Inhalation of penicillin dust JAMA - J. Am. Med. Assoc. 138 1948 344 348
11. J.H. Bell, P.S. Hartley, and J.S.G. Cox Dry powder aerosols I: a new powder inhalation device J. Pharm. Sci. 60 1971 1559 1564
12. M.M. Dykes Evaluation of an antiasthmatic agent cromolyn sodium (aarane, intal) JAMA - J. Am. Med. Assoc. 227 1974 1061 1062
13. S.P. Newman, A. Hollingworth, and A.R. Clark Effect of different modes of inhalation on drug delivery from a dry powder inhaler Int. J. Pharm. 102 1994 127 132
14. H. Steckel, and B.W. Müller In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices Int. J. Pharm. 154 1997 19 29
15. M.J. Telko, and A.J. Hickey Dry powder inhaler formulation Respir. Care 50 2005 1209 1227
16. F. Buttini, P. Colombo, A. Rossi, F. Sonvico, and G. Colombo Particles and powders: tools of innovation for non-invasive drug administration J. Controlled Release 2012 10.1016/j.jconrel.2012.1002.1028
17. M.P. Timsina, G.P. Martin, C. Marriott, D. Ganderton, and M. Yianneskis Drug delivery to the respiratory tract using dry powder inhalers Int. J. Pharm. 101 1994 1 13
18. Fachinformation Relenza 5 mg/Dosis (German Summary of Product Characteristics), GlaxoSmithKline GmbH & Co. KG, München, Germany, 2011.
19. J.G. Weers, T.E. Tarara, and A.R. Clark Design of fine particles for pulmonary drug delivery Expert Opin. Drug Delivery 4 2007 297 313
20. Y.-J. Son, and J.T. McConville Advancements in dry powder delivery to the lung Drug Dev. Ind. Pharm. 34 2008 948 959
21. X.M. Zeng, S. Jones, D. O'Leary, M. Phelan, and J. Colledge Delivery of formoterol from a novel multi-dose inhaler AirmaxTM Respir. Med. 96 2002 397 403
22. X.M. Zeng, D. O'Leary, M. Phelan, S. Jones, and J. Colledge Delivery of salbutamol and of budesonide from a novel multi-dose inhaler AirmaxTM Respir. Med. 96 2002 404 411
23. S. Newman, G. Pitcairn, P. Hirst, R. Bacon, E. O'Keefe, M. Reiners, and R. Hermann Scintigraphic comparison of budesonide deposition from two dry powder inhalers Eur. Respir. J. 16 2000 178 183
24. G.R. Pitcairn, T. Lankinen, O.-P. Seppälä, and S.P. Newman Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort J. Aerosol Med. 13 2000 97 104
25. PH&T. < http://www.phtpharma.com/images/volantino-turbospin.pdf > (accessed 05.07.12).
26. L. Valentini, M. Maiorano, Inhalation Device, United States Patent 4,069,819, Societa Farmaceutici S.p.A. (Milan, Italy), United States, 1978.
27. S. White, D.B. Bennett, S. Cheu, P.W. Conley, D.B. Guzek, S. Gray, J. Howard, R. Malcolmson, J.M. Parker, P. Roberts, N. Sadrzadeh, J.D. Schumacher, S. Seshadri, G.W. Sluggett, C.L. Stevenson, and N.J. Harper EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin Diabetes Technol. Ther. 7 2005 896 906
28. D.R. Owens, B. Zinman, and G. Bolli Alternative routes of insulin delivery Diabetic Med. 20 2003 886 898
29. M. Tobyn, J.N. Staniforth, D. Morton, Q. Harmer, and M.E. Newton Active and intelligent inhaler device development Int. J. Pharm. 277 2004 31 37
30. A.H. de Boer, P. Hagedoorn, E.M. Westerman, P.P.H. Le Brun, H.G.M. Heijerman, and H.W. Frijlink Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses Eur. J. Pharm. Sci. 28 2006 171 178
31. P.M. Young, J. Thompson, R. Price, D. Woodcock, and K. Davies The use of a novel handheld device to deliver high respirable fractions of high-dose dry powder active agents to the lung J. Aerosol Med. 16 2003 192
32. P.M. Young, J. Thompson, D. Woodcock, M. Aydin, and R. Price The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy J. Aerosol Med. 17 2004 123 128
33. R. Winkler, H. Wachtel, P. Langguth, Dose Range of a Propellant Driven High-Dose Dry Powder Inhaler, RDD Europe, Berlin, 2013, pp. 251-255.
34. D.S. Maltz, and S.J. Paboojian Device engineering insights into TOBI Podhaler: a development case study of high efficient powder delivery to cystic fibrosis patients R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, P.M. Young, Respiratory Drug Delivery Europe 2011, Davis Healthcare International Publishing (River Grove) 2011 Davis Healthcare International Publishing (River Grove, IL, USA) Berlin, Germany 55 65
35. J. Weers, K. Ung, J. Le, N. Rao, B. Ament, G. Axford, D. Maltz, and L. Chan Dose emission characteristics of placebo PulmoSphere((R)) particles are unaffected by a subject's inhalation maneuver J. Aerosol. Med. Pulm. Drug Delivery 2012
36. G. Pilcer, N. Wauthoz, and K. Amighi Lactose characteristics and the generation of the aerosol Adv. Drug Delivery Rev. 64 2012 233 256
37. P.M. Young, D. Cocconi, P. Colombo, R. Bettini, R. Price, D.F. Steele, and M.J. Tobyn Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing" J. Pharm. Pharmacol. 54 2002 1339 1344
38. H. Steckel, and B.W. Müller In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition Int. J. Pharm. 154 1997 31 37
39. X.M. Zeng, G.P. Martin, S.-K. Tee, and C. Marriott The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro Int. J. Pharm. 176 1998 99 110
40. J.N. Staniforth, Powder Comprising Anti-Adherent Materials for Use in Dry Powder Inhalers, United States Patent 6475523, Vectura Limited, United States, 2002.
41. M.-P. Flament, P. Leterme, and A. Gayot The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers Int. J. Pharm. 275 2004 201 209
42. A. Chow, H. Tong, P. Chattopadhyay, and B. Shekunov Particle engineering for pulmonary drug delivery Pharm. Res. 24 2007 411 437
43. M. Jones, and R. Price The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations Pharm. Res. 23 2006 1665 1674
44. P. Lucas, K. Anderson, and J.N. Staniforth Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers Pharm. Res. 15 1998 562 569
45. K. Wetterlin Turbuhaler: a new powder inhaler for administration of drugs to the airways Pharm. Res. 5 1988 506 508
46. T. Nakate, H. Yoshida, A. Ohike, Y. Tokunaga, R. Ibuki, and Y. Kawashima Formulation development of inhalation powders for FK888 using the E-haler® to improve the inhalation performance at a high dose, and its absorption in healthy volunteers Eur. J. Pharm. Biopharm. 59 2005 25 33
47. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
48. N. Rasenack, H. Steckel, and B.W. Müller Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process J. Pharm. Sci. 92 2003 35 44
49. H.-K. Chan What is the role of particle morphology in pharmaceutical powder aerosols? Expert Opin. Drug Delivery 5 2008 909 914
50. K. Ikegami, Y. Kawashima, H. Takeuchi, H. Yamamoto, N. Isshiki, D.-I. Momose, and K. Ouchi Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler® by polymorphic transformation to needle-like crystals (β-form) Pharm. Res. 19 2002 1439 1445
51. R.J. Malcolmson, and J.K. Embleton Dry powder formulations for pulmonary delivery Pharm. Sci. Technol. Today 1 1998 394 398
52. H.H.Y. Tong, B. Yu Shekunov, P. York, and A.H.L. Chow Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids Pharm. Res. 18 2001 852 858
53. S. Schüle, W. Frieß, K. Bechtold-Peters, and P. Garidel Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations Eur. J. Pharm. Biopharm. 65 2007 1 9
54. K. Cal, and K. Sollohub Spray drying technique. I: hardware and process parameters J. Pharm. Sci. 99 2010 575 586
55. R. Vehring Pharmaceutical particle engineering via spray drying Pharm. Res. 25 2008 999 1022
56. N.Y.K. Chew, and H.-K. Chan Use of solid corrugated particles to enhance powder aerosol performance Pharm. Res. 18 2001 1570 1577
57. N.Y.K. Chew, P. Tang, H.-K. Chan, and J.A. Raper How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm. Res. 22 2005 148 152
58. R. Fuhrherr, Spray-dried Antibody Powders for Pulmonary Application, PhD Thesis, Ludwig-Maximilians Universität München, Germany, 2005.
59. C. Weiler, M. Egen, M. Trunk, and P. Langguth Force control and powder dispersibility of spray dried particles for inhalation J. Pharm. Sci. 99 2010 303 316
60. R.P. Aquino, L. Prota, G. Auriemma, A. Santoro, T. Mencherini, G. Colombo, and P. Russo Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells Int. J. Pharm. 426 2012 100 107
61. D. Lechuga-Ballesteros, C. Charan, C.L.M. Stults, C.L. Stevenson, D.P. Miller, R. Vehring, V. Tep, and M.-C. Kuo Trileucine improves aerosol performance and stability of spray-dried powders for inhalation J. Pharm. Sci. 97 2008 287 302
62. K. Bechtold-Peters, W. Friess, S. Schuele, S. Bassarab, P. Garidel, T. Schultz-Fademrecht, Spray-Dried Amorphous Powder with a low Residual Moisture and Excellent Storage Stability, Boehringer Ingelheim Pharma GmbH & Co. KG (Binger Strasse 173, 55216 Ingelheim, DE), 2008.
63. R. Vanbever, J.D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D.A. Edwards Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 16 1999 1735 1742
64. D.E. Geller, J. Weers, and S. Heuerding Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology J. Aerosol Med. Pulm. Drug Delivery 24 2011 175 182
65. J. Weers Dispersible powders for inhalation applications Innov. Pharm. Tech. 7 2001 111 116
66. D.E. Geller, M.W. Konstan, J. Smith, S.B. Noonberg, and C. Conrad Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr. Pulm. 42 2007 307 313
67. H.R. Costantino, L. Firouzabadian, K. Hogeland, C. Wu, C. Beganski, K.G. Carrasquillo, M. Córdova, K. Griebenow, S.E. Zale, and M.A. Tracy Protein spray-freeze drying. Effect of atomization conditions on particle size and stability Pharm. Res. 17 2000 1374 1382
68. Y.-F. Maa, P.-A. Nguyen, T. Sweeney, S.J. Shire, and C.C. Hsu Protein inhalation powders: spray drying vs spray freeze drying Pharm. Res. 16 1999 249 254
69. H.R. Costantino, L. Firouzabadian, C. Wu, K.G. Carrasquillo, K. Griebenow, S.E. Zale, and M.A. Tracy Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability J. Pharm. Sci. 91 2002 388 395
70. A. Pfützner, and T. Forst Pulmonary insulin delivery by means of the Technosphere™ drug carrier mechanism Expert Opin. Drug Delivery 2 2005 1097 1106
71. A. Pfützner, F. Flacke, R. Pohl, D. Linkie, M. Engelbach, R. Woods, T. Forst, J. Beyer, and S.S. Steiner Technopshere/PTH(1-34) - a new approach for effective pulmonary delivery of parathyroid hormone(1-34) Horm. Metab. Res. 35 2003 319 323
72. A. Pfützner, A.E. Mann, and S.S. Steiner Technosphere/insulin - a new approach for effective delivery of human insulin via the pulmonary route Diabetes Technol. Ther. 4 2002 589 594
73. Fachinformation TOBI Podhaler (German Summary of Product Characteristics), Novartis Pharma GmbH, Nürnberg, Germany, 2011.
74. M.T. Newhouse, P.H. Hirst, S.P. Duddu, Y.H. Walter, T.E. Tarara, A.R. Clark, and J.G. Weers Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers Chest 124 2003 360 366
75. Colobreath Product Information, WC500123690, European Medicines Agency, 2012.
76. Tief in den Lungen, in: Bayer Research 21, Bayer AG, Leverkusen, Germany, 2011.
77. H. Stass, S. Baumann-Noss, H. Delesen, J. Nagelschmitz, S. Willmann, A. Edginton, Ciprofloxacin PulmoSpere inhalation powder: a healthy volunteer study, in: American Thoracic Society International Conference, Toronto, Canada, 2008.
78. Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics (NCT01537666), ClinicalTrails.gov (accessed 20.06.12).
79. Savara Pharmaceuticals, USA. News Section of Web Site: < http://www.savarapharma.com/news.html > (accessed 20.06.12).
80. S.D. Anderson, J. Brannan, J. Spring, N. Spalding, L.T. Rodwell, K. Cahn, I. Gonda, A. Walsh, and A.R. Clark A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol Am. J. Respir. Crit. Care Med. 156 1997 758 765
81. Fachinformation Aridol Pulver zur Inhalation (German Summary of Product Characteristics), Pharmaxis Pharmaceuticals Limited, Burnham, United Kingdom, 2010.
82. P. Jungmayr Ergänzender Baustein zur Therapie der Mukoviszidose Deut. Apotheker Zeitung 152 2012 38 40
83. * Chest 133 2008 1388 1396
84. A. Rawat, Q.H. Majumder, and F. Ahsan Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J. Controlled Release 128 2008 224 232
85. K.S. Babu, D.A. Woodcock, S.E. Smith, J.N. Staniforth, S.T. Holgate, and J.H. Conway Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma Eur. Respir. J. 21 2003 1046 1049
86. K. Holzer, S.D. Anderson, H.-K. Chan, and J. Douglass Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes Am. J. Respir. Crit. Care Med. 167 2003 534 537
87. M.W. Konstan, D.E. Geller, P. Minić, F. Brockhaus, J. Zhang, and G. Angyalosi Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial Pediatr. Pulm. 46 2011 230 238
88. M.W. Konstan, P.A. Flume, M. Kappler, R. Chiron, M. Higgins, F. Brockhaus, J. Zhang, G. Angyalosi, E. He, and D.E. Geller Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J. Cyst. Fibros. 10 2011 54 61